Literature DB >> 17207908

A single procalcitonin level does not predict adverse outcomes of women with pyelonephritis.

Virginie Lemiale1, Bertrand Renaud, Stéphane Moutereau, Alfred N'Gako, Mirna Salloum, Marie Jeanne Calmettes, Jérôme Hervé, Cyril Boraud, Aline Santin, Jean-Claude Grégo, François Braconnier, Eric Roupie.   

Abstract

OBJECTIVES: Predicting medical outcomes for pyelonephritis in women is difficult, leading to unnecessary hospitalization. Unlike other serious infectious diseases, high procalcitonin (PCT) level has never been associated with 28-d adverse medical outcomes in women with pyelonephritis. Therefore, we sought to determine the accuracy of PCT in discriminating between pyelonephritis with adverse medical outcome (PAMO) and pyelonephritis without adverse medical outcome (PWAMO). PATIENTS AND METHODS: Adult women with pyelonephritis presenting to the emergency department of a French tertiary care hospital were consecutively included. Those patients who developed adverse medical outcomes during a 28-d follow-up period were identified as having PAMO. Baseline characteristics and PCT level were compared between patients with PAMO and PWAMO.
RESULTS: Eleven women (19.0%) had PAMO and 47 (81%) had PWAMO. The median PCT level was higher in PAMO compared with PWAMO 0.51 ng/ml (IQR: 0.04-3.8) and 0.08 ng/ml (IQR: 0.01-1.0), but this difference was not statistically significant (p=0.07). We failed to find a threshold value for PCT that discriminated between PAMO and PWAMO (ROC, AUC=0.67 [95%CI, 0.51-0.86]). All but one subject with PAMO had either a PCT level >0.1 ng/ml or an underlying genitourinary abnormality by radiographic testing.
CONCLUSIONS: A single PCT level was a poor predictor of 28-d adverse medical outcomes in women with pyelonephritis treated in the emergency department. Prediction based on underlying genitourinary abnormality by radiographic testing in addition to the PCT level should be investigated in future studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17207908     DOI: 10.1016/j.eururo.2006.12.018

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  6 in total

1.  Update in adult urinary tract infection.

Authors:  Lindsay E Nicolle
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

2.  Reduced utility of early procalcitonin and blood culture determination in patients with febrile urinary tract infections in the emergency department.

Authors:  Marcello Covino; Alberto Manno; Giuseppe Merra; Benedetta Simeoni; Andrea Piccioni; Luigi Carbone; Evelina Forte; Veronica Ojetti; Francesco Franceschi; Rita Murri
Journal:  Intern Emerg Med       Date:  2019-10-24       Impact factor: 3.397

3.  Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study.

Authors:  Cees van Nieuwkoop; Tobias N Bonten; Jan W van't Wout; Ed J Kuijper; Geert H Groeneveld; Martin J Becker; Ted Koster; G Hanke Wattel-Louis; Nathalie M Delfos; Hans C Ablij; Eliane M S Leyten; Jaap T van Dissel
Journal:  Crit Care       Date:  2010-11-17       Impact factor: 9.097

4.  Useulness of B Natriuretic Peptides and Procalcitonin in Emergency Medicine.

Authors:  S Delerme; C Chenevier-Gobeaux; B Doumenc; P Ray
Journal:  Biomark Insights       Date:  2008-03-27

5.  Procalcitonin determined at emergency department as na early indicator of progression to septic shock in patient with sepsis associated with ureteral calculi.

Authors:  Young Hwii Ko; Yoon Seob Ji; Sin-Youl Park; Su Jin Kim; Phil Hyun Song
Journal:  Int Braz J Urol       Date:  2016 Mar-Apr       Impact factor: 1.541

6.  A diagnostic algorithm for detection of urinary tract infections in hospitalized patients with bacteriuria: The "Triple F" approach supported by Procalcitonin and paired blood and urine cultures.

Authors:  Kathrin Rothe; Christoph D Spinner; Birgit Waschulzik; Christian Janke; Jochen Schneider; Heike Schneider; Krischan Braitsch; Christopher Smith; Roland M Schmid; Dirk H Busch; Juri Katchanov
Journal:  PLoS One       Date:  2020-10-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.